Background: Apixaban is an oral, potent, highly selective, reversible and direct inhibitor of
activated coagulation factor X, that is the end point of the intrinsic and extrinsic coagulation …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

Abstract Background and Objectives The effects of age and sex on apixaban
pharmacokinetics and pharmacodynamics were studied. Methods This was an open-label …

Purpose This double-blind, placebo-controlled, intra-subject, dose-escalation study
assessed single-dose safety, pharmacokinetics, and pharmacodynamics of apixaban in …

Aims To evaluate apixaban single dose safety, tolerability, pharmacokinetics and
pharmacodynamics and assess the effect of food on apixaban pharmacokinetics. Methods A …

Background The pharmacokinetics (PK), pharmacodynamics (PD), and safety of apixaban
were assessed in healthy Chinese subjects in this randomized, placebo-controlled, double …

Purpose These studies evaluate the relative bioavailability of crushed apixaban tablets and
the effect of food on apixaban pharmacokinetic properties. Methods An open-label …

Background Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a
prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic …

Objective This was a randomized, placebo-controlled, double-blind, sequential, ascending-
dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of …

From the 1940s through 2010, warfarin (Coumadin, Bristol-Myers Squibb) was the only oral
anticoagulant on the market in the US for the treatment and prevention of thromboembolic …